Navigation Links
Dendreon Announces Presentation of PROVENGE Data at the American Urological Association Annual Meeting
Date:5/31/2010

ngs and process the antigen into fragments that are then displayed on the APC surface. Once displayed, these antigens can be recognized by specific classes of immune cells called T lymphocytes (T-cells), which are activated as a result of their engagement with APCs and combat disease by seeking antigen-bearing cells directly. PROVENGE is designed to target the prostate cancer antigen prostatic acid phosphatase (PAP), an antigen that is expressed in more than 95 percent of all prostate cancers.

About Dendreon

Dendreon Corporation is a biotechnology company targeting cancer and transforming lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first autologous cellular immunotherapy product, PROVENGE® (sipuleucel-T), was approved by the FDA in April 2010 for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. Dendreon also is developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer. The Company is headquartered in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit www.dendreon.com

This news release contains forward-looking statements that are subject to risks and uncertainties. Factors
'/>"/>

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Presents Updated IMPACT Results Confirming PROVENGE Improves Overall Survival in Patients With Metastatic Castrate-Resistant Prostate Cancer
2. Dendreon Reports Fourth Quarter and 2009 Year End Financial Results
3. Dendreon Announces Election of Ian Clark and Pedro Granadillo to Board of Directors
4. Dendreon Reports PROVENGE Regulatory and Commercialization Progress and Future Pipeline Plans at Analyst Event
5. Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia
6. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
7. Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial
8. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
9. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
10. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
11. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Cali ., Aug. 22, 2014  Research presented ... that a therapy being developed by Hera Therapeutics Inc. combats ... 70 percent of all cervical cancer. When tested ... of HPV-16, HPV-18 and HPV-11 cells, according to Louise ... who presented the findings at the Seattle ...
(Date:8/22/2014)... , Aug. 22, 2014  Cannabis Science, ... cannabis formulation-based drug development and related consulting, is ... third international medical cannabis conference taking place at ... France , on October 22, 2014.  The ... stakeholders, such as researchers, health professionals, and patients, ...
(Date:8/22/2014)...  WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today announced the ... common stock and warrants at a price of $10,000 ... to deducting underwriting discounts and commissions and offering expenses ... immediately separable and will be issued separately.  The shares ... The NASDAQ Stock Market under the ticker symbol "WGBS" ...
Breaking Medicine Technology:Study shows Hera Therapeutics experimental compound shuts down human papillomavirus that causes most cervical cancer 2Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 2Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4
... 2011 Sigma-Aldrich Corporation (NASDAQ: SIAL ) ... unit, SAFC® ( www.safcglobal.com ), is introducing a novel ... (CHO) cell line. Designed for use in the production ... the first commercially available glutamine synthetase (GS) knockout CHO ...
... YORK, Oct. 27, 2011 Reportlinker.com ... report is available in its catalogue: ... Reimbursement Outlook: Optimizing price and market ... http://www.reportlinker.com/p0165652/Pharma-Pricing-and-Reimbursement-Outlook-Optimizing-price-and-market-access-in-a-recessionary-climate.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Health_Insurance ...
Cached Medicine Technology:SAFC Introduces the First Commercially Available Novel CHOZN® GS Knockout CHO Cell Line 2SAFC Introduces the First Commercially Available Novel CHOZN® GS Knockout CHO Cell Line 3SAFC Introduces the First Commercially Available Novel CHOZN® GS Knockout CHO Cell Line 4Pharma Pricing and Reimbursement Outlook: Optimizing price and market access in a recessionary climate 2Pharma Pricing and Reimbursement Outlook: Optimizing price and market access in a recessionary climate 3Pharma Pricing and Reimbursement Outlook: Optimizing price and market access in a recessionary climate 4Pharma Pricing and Reimbursement Outlook: Optimizing price and market access in a recessionary climate 5
(Date:8/22/2014)... NV (PRWEB) August 22, 2014 Natural ... Kevin Richardson to restore his own vision from legally blind ... Michaels, prompting an investigative review. , “There is a ... or contacts for everyday function, and most people just think ... to corrective eye surgery that can be pretty risky at ...
(Date:8/22/2014)... factor receptor (EGFR) mutations found in the circulating free ... cell lung cancer (NSCLC) patients correlates well with the ... tyrosine kinase inhibitor (TKI) therapy is approved for EGFR ... standard for determining mutation status is with DNA derived ... not available. A more abundant and less invasive source ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Testosterone ... filed in U.S. courts on behalf of men ... their use of prescription low testosterone therapies, Bernstein ... new claim was filed against Pfizer Inc. on ... suffered life-threatening heart issues due to his use ...
(Date:8/22/2014)... Aug. 22, 2014 (HealthDay News) -- An intensive effort to ... an animal shelter in Florida and euthanized, a new study ... cats to slow their intake into animal control," Dr. Julie ... Florida College of Veterinary Medicine, said in a university news ... wasn,t making a big impact," she explained, "so we wanted ...
(Date:8/22/2014)... artery stenting to open blockages in the kidney ... excluded from modern clinical trials, according to new ... Catheterization and Cardiovascular Interventions today by the ... University Hospitals Case Medical Center,s Sahil Parikh, MD, ... Medicine, Case Western Reserve University School of Medicine ...
Breaking Medicine News(10 mins):Health News:Natural Clear Vision: Review Exposes Kevin Richardson’s Program for Restoring Vision Naturally 2Health News:High concordance between EGFR mutations from circulating-free tumor DNA and tumor tissue in non-small cell lung cancer 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 4Health News:Neutering Project Curbed Feral Cat Population 2Health News:UH Case Medical Center's Dr. Parikh authors SCAI paper on renal artery stenosis treatment 2Health News:UH Case Medical Center's Dr. Parikh authors SCAI paper on renal artery stenosis treatment 3
... iodinated contrast media during imaging procedures is associated ... of developing hyperthyroidism, according to a report in ... Internal Medicine , one of the JAMA/Archives journals. ... pharmaceutical agents," the authors write as background information. ...
... Reporter , MONDAY, Jan. 23 (HealthDay News) -- Although many ... seriously hurt, the opposite may be true with traumatic brain ... traumatic brain injury in children as young as 2 years, ... even behavior for some time. However, the researchers also found ...
... who routinely accompany older adults to physician office visits ... according to a new study led by researchers at ... authors found that three-quarters of older adults who attend ... over time, nearly always by the same companion. The ...
... release is available in French . Montreal ... three times more likely to develop respiratory or gastrointestinal infections in ... as a Centre d,Hbergement de Soins de Longue Dure (CHLSD). These ... Canadian Medical Association Journal today. "There certainly seems ...
... can help fight both breast cancers and leukemias, according to ... Journal of Experimental Medicine ( http://www.jem.org ). The ... protect other proteins in the cell. , A team led ... found that blocking HSP90 activity rendered normally protected proteins vulnerable ...
... garnered accolades for rescuing skinned knees on the playground ... they,re gaining merit for their offspring,s physical health in ... the journal Psychological Science , Brandeis psychologist Margie ... of British Columbia and the University of California, Los ...
Cached Medicine News:Health News:Use of iodinated contrast media in imaging procedures appears to affect thyroid function 2Health News:Severe Brain Injury When Young May Have Long-Term Effects 2Health News:Severe Brain Injury When Young May Have Long-Term Effects 3Health News:Severe Brain Injury When Young May Have Long-Term Effects 4Health News:Going to physician visits with older loved ones could improve care 2Health News:Emergency room visits risky for elderly residents from long-term care facilities 2Health News:Nurturing mothers rear physically healthier adults 2Health News:Nurturing mothers rear physically healthier adults 3
... The 1081 is an all-in-one drape ... The drape includes a pouch with filter ... finger cot. 64 inches (164cm) TUR ... Elastic aperture, Neoprene finger cot, Fluid collection ...
... Both the Penilab IV and the Penilab V ... studies. Model 1060 is similar to the Model ... nor can one be added later. The Penilab ... including all of the accessories you'll need to get ...
The Model 240 is a single-channel instrument designed for penile tumescence monitoring. It features exceptional stability. It's ready for use with most multi-channel recorders having a DC input....
... II SP MRI-Compatible Anesthesia System is perfect for ... than one type of anesthetic agent. , ... due to its wider stance, has a larger ... bellows assembly is utilized in both the Integra ...
Medicine Products: